logo

DermNet NZ


Facts about the skin from DermNet New Zealand Trust. Topic index: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Cutaneous polyarteritis nodosa

Cutaneous polyarteritis nodosa (PAN) is a rare form of vasculitis (inflammation of blood vessels) that involves small and medium-sized arteries of the dermis and subcutaneous tissue i.e. the deeper layers of the skin. It is sometimes called periarteritis nodosa.

Although identical skin lesions are common in systemic PAN, cutaneous PAN should be considered a separate disease and distinguished from systemic PAN as the clinical course and management of these conditions differ from each other. PAN is a vasculitis that causes destructive inflammation of medium-sized muscular arteries of multiple systems including the liver, kidney, heart, lung, gastrointestinal tract, musculoskeletal and nervous systems. Systemic PAN is a potentially life-threatening form of vasculitis whereas cutaneous PAN usually runs a chronic but benign course.

What is the cause of cutaneous PAN?

In many cases the cause is not known. However, in some cases it appears to be a hypersensitivity reaction to certain infections, particularly Group A streptococcus, hepatitis B, Hepatitis C, Human Immunodeficiency virus, Parvovirus B19 (Fifth disease). There is an over-reaction of the immune system to the infection.

What are the signs and symptoms of cutaneous PAN?

Cutaneous polyarteritis nodosa Cutaneous polyarteritis nodosa Cutaneous polyarteritis nodosa
Cutaneous polyarteritis nodosa

Lesions are most often found on the legs and feet. Other areas that may be affected include the arms, trunk, buttocks, and head and neck. They are most likely on pressure points such as the knees, back of the foot and lower leg.

In addition to the skin problems, patients may also have generalised symptoms such as malaise, fever, sore throat, and joint and muscle aches and pains. Neurological symptoms may also be present and include numbness, tingling, sensory disturbances, weakness, and absent reflexes.

Diagnosis of cutaneous PAN

Skin biopsy of a typical lesion is often performed to make an accurate diagnosis of cutaneous PAN. A specimen showing panarteritis (inflammation of all blood vessels in the skin sample) is the only definitive proof of PAN.

Laboratory tests of blood samples are generally unhelpful in diagnosing or monitoring cutaneous PAN, as blood counts and chemistry are often normal. They are initially required to determine the cause of vasculitis or to exclude other organ involvement as occurs in systemic PAN.

What is the treatment of cutaneous PAN?

Cutaneous PAN usually runs a chronic course lasting from months to years with exacerbations and remissions. Neurological symptoms and muscular aches and pains usually resolve over a matter of months whilst skin lesions take longer to heal.

Remissions may occur spontaneously or after treatment with oral corticosteroids , cyclophosphamide or other immunosuppressive medications used to control the acute exacerbation and relieve pain. They can be stopped as symptoms become less severe or subside. Intravenous immunoglobulins have been used successfully.

Non-steroidal anti-inflammatory drugs are also used and are suitable alternative first-line agents in patients when corticosteroids are contraindicated. Colchicine may also be used.

Ulcerating skin lesions may be treated with bland topical preparations such as active manuka honey and covered with special dressings to improve healing. Occasionally skin grafts are advised but they may fail because of the damage to the blood vessels supplying nutrition to the skin.

If the PAN is caused by streptococcal infection, it is wise to remain on long term penicillin to prevent further attacks such as streptococcal tonsillitis or cellulitis.

Viral infections may sometimes respond to a course of an antiviral agent.

Warfarin (with a international normalised ratio [INR] of 3) has been reported to be effective in 3 cases of cutaneous polyarteritis nodosa with improvement in livedo reticularis and healing of ulcers.

In a few cases, over time cutaneous PAN may progress to systemic PAN. Patients with cutaneous PAN should be followed-up regularly so that any signs of progress to the systemic form may be picked up early.

Related information

References:

On DermNet NZ:

Other websites:

Medscape Reference:

Books:

See the DermNet NZ bookstore

Author: Vanessa Ngan, staff writer

DermNet NZ does not provide an online consultation service.
If you have any concerns with your skin or its treatment, see a dermatologist for advice.